The pooled prevalence of ATM in patients with breast cancer in several continent was 7% (95% CI: 5−8%; I square: 98%; P: 0.00), 5% (95% CI: 1−11%; I square: 80%; P: 0.01) and 9% (95% CI: 4−14%; I square: 96%; P: 0.00) for European, Asian and American population, respectively (Table 2). Here, ATM is linked to breast carcinoma.